Dr. Heymach on Nivolumab for Lung Cancer

John V. Heymach, MD, PhD
Published: Friday, Apr 14, 2017



John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy findings with nivolumab (Opdivo) results for patients with metastatic lung cancer.

There is now 5 years of follow-up for patients treated with nivolumab, explains Heymach. This is one of the first studies that demonstrated a positive result from immunotherapy for patients with metastatic lung cancer.

This is a significant step forward in the field, states Heymach. Patients are now becoming long-term survivors, making immunotherapy a viable treatment option.
 
SELECTED
LANGUAGE


John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy findings with nivolumab (Opdivo) results for patients with metastatic lung cancer.

There is now 5 years of follow-up for patients treated with nivolumab, explains Heymach. This is one of the first studies that demonstrated a positive result from immunotherapy for patients with metastatic lung cancer.

This is a significant step forward in the field, states Heymach. Patients are now becoming long-term survivors, making immunotherapy a viable treatment option.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x